Anthony Petrone
Stock Analyst at Mizuho
(3.99)
# 469
Out of 4,826 analysts
168
Total ratings
52.03%
Success rate
8.85%
Average return
Main Sectors:
Stocks Rated by Anthony Petrone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GKOS Glaukos | Maintains: Outperform | $200 → $175 | $86.86 | +101.47% | 8 | Apr 16, 2025 | |
| EMBC Embecta | Initiates: Neutral | $15 | $12.52 | +19.81% | 1 | Apr 10, 2025 | |
| GH Guardant Health | Initiates: Outperform | $55 | $44.05 | +24.86% | 1 | Apr 10, 2025 | |
| SENS Senseonics Holdings | Initiates: Outperform | $2 | $0.67 | +198.37% | 1 | Apr 10, 2025 | |
| TNDM Tandem Diabetes Care | Initiates: Neutral | $20 | $21.33 | -6.24% | 1 | Apr 10, 2025 | |
| DXCM DexCom | Initiates: Outperform | $85 | $80.25 | +5.92% | 1 | Apr 10, 2025 | |
| EXAS Exact Sciences | Initiates: Outperform | $60 | $53.32 | +12.53% | 1 | Apr 10, 2025 | |
| ALC Alcon | Maintains: Outperform | $115 → $120 | $97.38 | +23.23% | 9 | Mar 28, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $54 → $58 | $48.02 | +20.78% | 2 | Mar 6, 2025 | |
| LIVN LivaNova | Maintains: Outperform | $70 → $60 | $36.29 | +65.36% | 8 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $87 | $52.73 | +64.99% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $275 → $250 | $122.86 | +103.48% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $110 | $104.24 | +5.53% | 8 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $115 → $130 | $132.60 | -1.96% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $14 | $23.71 | -40.95% | 6 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $70 | $33.51 | +108.89% | 6 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $55 | $18.98 | +189.78% | 7 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $100 | $107.98 | -7.39% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $105 | $69.37 | +51.36% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $105 | $75.20 | +39.63% | 7 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $215 | $240.66 | -10.66% | 15 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $250 | $160.17 | +56.08% | 6 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $6.62 | +111.48% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $103 → $115 | $81.61 | +40.92% | 14 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $98 | $83.35 | +17.58% | 4 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $350 → $390 | $531.82 | -26.67% | 6 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $63 → $67 | $80.44 | -16.71% | 2 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $115 | $62.49 | +84.03% | 14 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $175 | $90.48 | +93.41% | 3 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $25 | $8.46 | +195.68% | 3 | May 13, 2020 |
Glaukos
Apr 16, 2025
Maintains: Outperform
Price Target: $200 → $175
Current: $86.86
Upside: +101.47%
Embecta
Apr 10, 2025
Initiates: Neutral
Price Target: $15
Current: $12.52
Upside: +19.81%
Guardant Health
Apr 10, 2025
Initiates: Outperform
Price Target: $55
Current: $44.05
Upside: +24.86%
Senseonics Holdings
Apr 10, 2025
Initiates: Outperform
Price Target: $2
Current: $0.67
Upside: +198.37%
Tandem Diabetes Care
Apr 10, 2025
Initiates: Neutral
Price Target: $20
Current: $21.33
Upside: -6.24%
DexCom
Apr 10, 2025
Initiates: Outperform
Price Target: $85
Current: $80.25
Upside: +5.92%
Exact Sciences
Apr 10, 2025
Initiates: Outperform
Price Target: $60
Current: $53.32
Upside: +12.53%
Alcon
Mar 28, 2025
Maintains: Outperform
Price Target: $115 → $120
Current: $97.38
Upside: +23.23%
Tarsus Pharmaceuticals
Mar 6, 2025
Maintains: Buy
Price Target: $54 → $58
Current: $48.02
Upside: +20.78%
LivaNova
Feb 26, 2025
Maintains: Outperform
Price Target: $70 → $60
Current: $36.29
Upside: +65.36%
Nov 5, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $52.73
Upside: +64.99%
Nov 1, 2024
Maintains: Neutral
Price Target: $275 → $250
Current: $122.86
Upside: +103.48%
Oct 24, 2024
Maintains: Outperform
Price Target: $100 → $110
Current: $104.24
Upside: +5.53%
Oct 17, 2024
Maintains: Neutral
Price Target: $115 → $130
Current: $132.60
Upside: -1.96%
Jun 20, 2024
Maintains: Buy
Price Target: $12 → $14
Current: $23.71
Upside: -40.95%
Jun 6, 2024
Maintains: Buy
Price Target: $65 → $70
Current: $33.51
Upside: +108.89%
May 8, 2024
Maintains: Buy
Price Target: $53 → $55
Current: $18.98
Upside: +189.78%
May 3, 2024
Maintains: Buy
Price Target: $90 → $100
Current: $107.98
Upside: -7.39%
May 1, 2024
Maintains: Buy
Price Target: $110 → $105
Current: $69.37
Upside: +51.36%
Apr 11, 2024
Maintains: Buy
Price Target: $95 → $105
Current: $75.20
Upside: +39.63%
Mar 27, 2024
Maintains: Buy
Price Target: $215
Current: $240.66
Upside: -10.66%
Mar 27, 2024
Maintains: Buy
Price Target: $250
Current: $160.17
Upside: +56.08%
Mar 1, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $6.62
Upside: +111.48%
Mar 1, 2024
Maintains: Buy
Price Target: $103 → $115
Current: $81.61
Upside: +40.92%
Feb 21, 2024
Maintains: Buy
Price Target: $95 → $98
Current: $83.35
Upside: +17.58%
Jan 25, 2024
Maintains: Neutral
Price Target: $350 → $390
Current: $531.82
Upside: -26.67%
Aug 3, 2023
Downgrades: Hold
Price Target: $63 → $67
Current: $80.44
Upside: -16.71%
Feb 8, 2023
Maintains: Buy
Price Target: $110 → $115
Current: $62.49
Upside: +84.03%
Nov 5, 2021
Maintains: Buy
Price Target: $200 → $175
Current: $90.48
Upside: +93.41%
May 13, 2020
Maintains: Hold
Price Target: $30 → $25
Current: $8.46
Upside: +195.68%